Figure S2. Cost Effectiveness Acceptability Curve (CEAC), complete case Child Health Utility 9D (CHU-9D) at 2 years

This CEAC shows the probability of the emolleint intervention being cost effective estimated as 29% (36%) at a willingness to pay threshold of £20,000 (£30,000) per Quality Adjusted Life Year (QALY). The figure suggests the emollient intervention is unlikely to be viewed as cost-effective effective compared to usual care in the BEEP trial. ICER denotes incremental cost-effectiveness ratio.